Zobrazeno 1 - 10 of 12 pro vyhledávání: '"Elizabeth Laureen Strevel"'
1
Cardiovascular toxicity of molecularly targeted agents
Autor: Elizabeth Laureen Strevel, Lillian L. Siu
Publikováno v: European Journal of Cancer. 45:318-331
Over the last decade, molecularly targeted drugs have become established in oncology therapeutics and clinical research. While initially marketed as “cancer specific” agents with superior toxicity profiles to conventional anti-proliferative and D
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ead7457c3a563c13489d71b96fc6480f
https://doi.org/10.1016/s0959-8049(09)70046-2
Zobrazit plný text záznamu
2
A pooled exploratory analysis of the effect of tumor size and KRAS mutations on survival benefit from adjuvant platinum-based chemotherapy in node-negative non-small cell lung cancer
Autor: Caroline Domerg, Ming-Sound Tsao, Frances A. Shepherd, Stephen L. Graziano, Sinead Cuffe, Elizabeth Laureen Strevel, Monia Ezzalfani, Pasi A. Jänne, Marzia Capelletti, Lesley Seymour, Ronald Burkes, Abderrahmane Bourredjem, Jean-Pierre Pignon
Publikováno v: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 7(6)
Introduction The staging of node-negative non–small-cell lung cancer is modified in the 7th edition TNM classification. Here, we pool data from the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial and the Cancer and Leukemia G
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b9df11698c44297ace97b5b06da942c
https://pubmed.ncbi.nlm.nih.gov/22588152
Zobrazit plný text záznamu
3
In a survey, marked inconsistency in how oncologists judged value of high-cost cancer drugs in relation to gains in survival
Autor: Eric Nadler, Peter A. Ubel, William K. Evans, Jennifer A. Palmer, Peter J. Neumann, Scott R. Berry, Chaim M. Bell, Elizabeth Laureen Strevel, Michael A. Kozminski
Publikováno v: Health affairs (Project Hope). 31(4)
Amid calls for physicians to become better stewards of the nation's health care resources, it is important to gain insight into how physicians think about the cost-effectiveness of new treatments. Expensive new cancer treatments that can extend life
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a08d9e388202bae764d3a1457b0cb0bb
https://pubmed.ncbi.nlm.nih.gov/22492887
Zobrazit plný text záznamu
4
Variation and Consternation: Access to Unfunded Cancer Drugs in Canada
Autor: Scott R. Berry, Elizabeth Laureen Strevel, William K. Evans, Chaim M. Bell
New anticancer drugs are improving outcomes for patients with cancer but at significant cost, and some publically funded health care systems have chosen not to fund these medications. Accessing these unfunded drugs concerns patients, challenges their
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::db224e0dbe25297cb264d1987f7a9ffa
https://europepmc.org/articles/PMC3266314/
Zobrazit plný text záznamu
5
Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs
Autor: Eric Nadler, Peter J. Neumann, William K. Evans, Scott R. Berry, Peter A. Ubel, Chaim M. Bell, Elizabeth Laureen Strevel
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(27)
Purpose Oncologists in the United States and Canada work in different health care systems, but physicians in both countries face challenges posed by the rising costs of cancer drugs. We compared their attitudes regarding the costs and cost-effectiven
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ef8fe2e93fe1839b52663f0cbc2e5e8
https://pubmed.ncbi.nlm.nih.gov/20697077
Zobrazit plný text záznamu
6
Time to adjuvant chemotherapy (AC) in stage III colon cancer at a community cancer center: A quality improvement initiative
Autor: Jeff Myers, Arun Partridge, Elizabeth Laureen Strevel, Katherine Enright, Cindy L. Quinton, Leonard Kaizer, Sudhashree Rajagopal, Mark Rother
Publikováno v: Journal of Clinical Oncology. 31:e17503-e17503
e17503 Background: The standard of care for stage III colon cancer remains 5FU based AC. In clinical trial settings, this begins within 56 days of surgery. Recently a meta-analysis suggested that delays to starting chemotherapy are associated with in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a18279180af4e9188aa26f2a871be60
https://doi.org/10.1200/jco.2013.31.15_suppl.e17503
Zobrazit plný text záznamu
9
Phase II trial of temsirolimus and bevacizumab for initial recurrence of endometrial cancer
Autor: Elizabeth Laureen Strevel, Mihaela C. Cristea, Mark H. Einstein, Rui Qin, Amit M. Oza, Robert M. Wenham, Andreas Kaubisch, Robert J. Morgan, Briant Fruth, Charles Erlichman
Publikováno v: Journal of Clinical Oncology. 30:5025-5025
5025 Background: We report the interim results of the endometrial arm of a multi-tumor protocol using temsirolimus and bevacizumab in endometrial cancer (EMCA) patients at the time of their initial recurrence. The primary aim of this trial is to asse
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::facce262e84b357b84e63505d0757e15
https://doi.org/10.1200/jco.2012.30.15_suppl.5025
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje